ADAMTS13 Inhibitor
Also known as: ADAMTS IN
Use
The ADAMTS13 Inhibitor test is primarily used to assist in distinguishing between inherited and acquired forms of thrombotic thrombocytopenic purpura (TTP). It is recommended as the initial test for identifying autoantibodies to ADAMTS13, as the inhibitor test is more specific for acquired TTP compared to the ADAMTS13 antibody test. In idiopathic TTP cases, autoantibodies that neutralize ADAMTS13 function can be identified and measured using this test.
Special Instructions
If suspicion for TTP remains after a negative result, the ADAMTS13 Antibody (3000182) is recommended. Correlation with clinical information, ADAMTS13 activity, and other relevant laboratory testing is suggested. Separate specimens must be submitted when multiple tests are ordered.
Limitations
ADAMTS13 Inhibitor test does not detect non-neutralizing autoantibodies, which can result in increased ADAMTS13 clearance but do not inhibit its function. Such non-neutralizing antibodies are detectable by ELISA using the ADAMTS13 antibody test. The test is not applicable for congenital TTP (Upshaw-Schulman syndrome) as ADAMTS13 autoantibodies are not present in such cases.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 40824-5
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
1 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Light Blue (Sodium Citrate) tube. Refer to Specimen Handling at aruplab.com for guidelines.
Storage Instructions
CRITICAL FROZEN.
Causes for Rejection
Serum or EDTA plasma, clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 hours |
| Refrigerated | Unacceptable |
| Frozen | 2 weeks (No freeze/thaw cycles.) |